Carcinoma

The supplied material does not support a single general cause for carcinoma. One review notes that some carcinomas, such as nasopharyngeal carcinoma, are closely related to Epstein-Barr virus infection. More broadly, tumor development is described as involving cancer cells evolving mechanisms that allow them to evade immune destruction.

Carcinoma biology in the supplied reviews centers on immune evasion within the tumor microenvironment. Tumors can develop suppressive and heterogeneous microenvironments that mimic peripheral immune tolerance, allowing malignant epithelial cells to escape cytotoxic innate and adaptive immune attack. This immune escape supports invasion, metastasis, treatment resistance, and recurrence, and is linked in one example to EBV-associated nasopharyngeal carcinoma.

The supplied grounding does not support general risk factors for carcinoma. For nasopharyngeal carcinoma specifically, Epstein-Barr virus infection is described as closely related to pathogenesis. The presence of a suppressive tumor microenvironment is described as promoting tumorigenesis, but this is presented as a disease feature rather than a general external risk factor.

The supplied material supports immunotherapy as a treatment modality under study for carcinoma, including immune-targeting approaches aimed at tumor immune escape. Pembrolizumab is the only specific drug mentioned in the grounding, but no regimen or disease-specific standard treatment pathway is provided. The abstracts also point to targeting the tumor microenvironment and immune escape mechanisms as therapeutic strategies.